Why Johnson & Johnson’s new ETHICON 4000 stapler could matter for European surgical workflow economics
Read how Johnson & Johnson’s ETHICON 4000 CE Mark approval could reshape surgical stapling, hospital economics, and future robotic integration.
Why Johnson & Johnson’s May 19 RBC fireside chat matters more than it first appears
Johnson & Johnson will join RBC Healthcare 2026 on May 19. Read why investors will watch the fireside chat for growth, guidance, and risk signals.
How Biora Therapeutics’ BioJet platform may reshape needle-free delivery for peptides and antibodies
How Biora Therapeutics’ BioJet may reshape needle-free delivery for peptides and antibodies. Read the full PDN analysis on what changes next.
Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears
electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.
Why the Nanodropper–Bedo–Viseon merger could reset the rules of personalized eyecare
Mu Medical unites Nanodropper, Bedo, and Viseon into a precision eyecare platform. Find out what this could mean for the future of AI-led ophthalmology.